Osilodrostat

Osilodrostat
Clinical data
Other names	LCI-699
Routes of; administration	By mouth
Identifiers
	IUPAC name 4-[(5R)-6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile;
CAS Number	928134-65-0;
PubChem CID	44139752;
ChemSpider	29340911;
UNII	5YL4IQ1078;
KEGG	D11061;
ChEMBL	ChEMBL3099695;
Chemical and physical data
Formula	C13H10FN3
Molar mass	227.242 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC2=CN=CN2[C@H]1C3=C(C=C(C=C3)C#N)F;
	InChI InChI=1S/C13H10FN3/c14-12-5-9(6-15)1-3-11(12)13-4-2-10-7-16-8-17(10)13/h1,3,5,7-8,13H,2,4H2/t13-/m1/s1; Key:USUZGMWDZDXMDG-CYBMUJFWSA-N;

Osilodrostat (INN, USAN) (developmental code name LCI-699) is an orally active, nonsteroidal corticosteroid biosynthesis inhibitor which is under development by Novartis for the treatment of Cushing's syndrome and pituitary ACTH hypersecretion (a specific subtype of Cushing's syndrome).[1][2] It specifically acts as a potent and selective inhibitor of aldosterone synthase (CYP11B2) and at higher dosages of 11β-hydroxylase (CYP11B1).[2] The drug was also under development for the treatment of heart failure, hypertension, and solid tumors, but development was discontinued for these indications.[1] As of 2017, osilodrostat is in phase III and phase II clinical trials for treatment of pituitary ACTH hypersecretion and Cushing's syndrome, respectively.[1]

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.